|
| Wednesday, February 26, 2014 |
|
|
Cytokinetics Announces Closing of its Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the closing of its previously announced underwritten public offering of 4,375,000 shares of its common stock, as well as 656,250 additional shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional shares. more info >> |
|
| Friday, February 21, 2014 |
|
|
Cytokinetics Announces pricing of $35.0 Million Public Offering of Common Stock |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the pricing of its previously announced underwritten public offering of 4,375,000 shares of its common stock at a price to the public of $8.00 per share. more info >> |
|
| Thursday, February 20, 2014 |
|
|
Cytokinetics Announces Proposed Public Offering of Common Stock |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. more info >> |
|
| Friday, February 7, 2014 |
|
|
Cytokinetics, Incorporated Reports Fourth Quarter 2013 Financial Results |
| Cytokinetics, Incorporated (Nasdaq: CYTK) reported total revenues of $24.3 million for the fourth quarter of 2013, compared to $2.2 million during the same period in 2012. Net income for the fourth quarter was $6.5 million, or $0.22 per basic share and $0.21 per diluted share. more info >> |
|
| Wednesday, February 5, 2014 |
|
|
Cytokinetics to Present at Upcoming Healthcare Conferences |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to participate at the following healthcare conferences. more info >> |
|
| Friday, January 24, 2014 |
|
|
Cytokinetics to Announce Fourth Quarter Results on February 6, 2014 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report fourth quarter results on Thursday, February 6, 2014 at 4:00 PM Eastern Time. more info >> |
|
| Monday, January 13, 2014 |
|
|
Cytokinetics Provides Updates Regarding Clinical Development Program for Omecamtiv Mecarbil |
| Cytokinetics, Incorporated (Nasdaq: CYTK) provided updates today regarding COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) and other progress in the development of omecamtiv mecarbil. more info >> |
|
| Tuesday, December 10, 2013 |
|
|
Cytokinetics Announces Results from First-Time-In-Humans Clinical Trial of CK-2127107 at Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the results from a first-time-in-humans clinical trial of CK-2127107 in healthy male volunteers were presented during a Late Breaking Clinical Trials session at the 7th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders in Kobe, Japan. more info >> |
|
| Monday, December 9, 2013 |
|
|
Cytokinetics Announces Presentation Providing Update on BENEFIT-ALS at International Symposium on ALS/MND |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that a platform presentation of data from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) was given at the 24th International Symposium on ALS/MND on December 7, 2013 in Milan, Italy. more info >> |
|
| Wednesday, December 4, 2013 |
|
|
Cytokinetics to Present Data Related to Skeletal Muscle Activators at Conference of Society on Sarcopenia, Cachexia and Wasting Disorders |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that two presentations, relating to its fast skeletal muscle troponin activators, are scheduled to be presented at the 7th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders from December 9-11, 2013 in Kobe, Japan. more info >> |
|
|
|
